• 2018 Annual Meeting
    “Balanced Approaches to Acute and Chronic Pain”
    Sept 21-23, 2018 | Atlanta, Georgia

    Our 32nd Annual Meeting will take place in Atlanta this year, from September 21 – 23. We will explore balanced approaches to acute and chronic pain which affects healthcare practitioners. Attendees will be provided with practical, exportable solutions that can be immediately implemented in their daily practice.

    2018 Annual Meeting Syllabus available here:

  • 1

We educate you.

Our members enjoy quality pain management education through our annual regional and district meetings.

We advocate for you.

SPS works through our districts and at a regional level to advocate for pain management policy to enhance your patient care.

We inform you.

Our members receive our quarterly newsletter plus additional posts through our blog to stay informed on the practice of management.

Stay informed with our latest pain management articles!

Is Compassion the Ghost of Pain Management?

Historically, the interactions between health care providers and patients involved a therapeutic component that enhanced the beneficial effect of the medications and treatments which were provided. Today, when they sense empathy and compassion from clinicians, patients continue to report greater satisfaction, less anxiety, and feeling safer, with improved outcomes demonstrated. Although compassion clearly is important in health care, it is often misunderstood.

Read More

Atlanta 2018–Our Most Relevant Conference

Barely a week goes by without at least one, often multiple, mainstream news articles about the practice of pain management. Just the other day, there were a number of stories about a huge federal multi-state crackdown on “rogue prescribing” of opiate pain medications by 76 doctors which led to them being arrested for fraud and a long list of other charges. We also read of a dramatic increase in raids on nationally prominent specialists in opiate dependence who prescribe buprenorphine.

Read More

CGRP Antagonists: Long-term Side Effects

The monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) are a valuable addition to our preventives. However, there are significant conceivable long-term adverse effects associated with them. We will have a better feel for the true risks in 10 years. For each patient, we have to decide whether the benefits outweigh the possible risks. With luck, it may come to pass that the biologics targeting CGRP carry very few long-term risks.

Read More

Support Southern Pain Society!

Our corporate members listed below help to further the Society's mission. We are grateful for their participation.

Teva Pharmaceutical Industries, Ltd.
Compass Laboratory Services